Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

22.32 +1.07 (+5.04%)
Streaming Delayed Price Updated: 10:48 AM EST, Dec 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Presents an Affordable Growth Opportunity ↗
Discover Apellis Pharmaceuticals (APLS), an affordable growth stock with strong revenue growth, fair valuation, and solid financial health for investors. 
Via Chartmill
News headline image
This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power ↗
Apellis reports five-year Syfovre data showing up to 31% slower GA lesion growth, reinforcing strong long-term efficacy and analyst optimism. 
Via Benzinga
News headline image
Earnings Scheduled For October 30, 2025 ↗
 
Via Benzinga
Apellis Short Bets Edge Higher As Stock Jumps 45% Since Late July Q2 Report — Retail Traders Stay Wary ↗
Via Stocktwits
News headline image
Earnings Scheduled For July 31, 2025 ↗
 
Via Benzinga
News headline image
Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
This Brinker International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
These stocks are moving in today's session ↗
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Here are the top movers in Thursday's session. ↗
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
The market is filled with gapping stocks in Thursday's session. ↗
Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Apellis Pharmaceuticals Inc (NASDAQ:APLS) Reports Strong Q3 2025 Earnings Beat ↗
Apellis Pharmaceuticals (APLS) Q3 2025 earnings crushed estimates, driven by strong drug sales and a major partnership payment. The company achieved profitability and positive market reaction. 
Via Chartmill
News headline image
Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Insights Ahead: Apellis Pharmaceuticals's Quarterly Earnings ↗
 
Via Benzinga
News headline image
New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 11 Analysts ↗
 
Via Benzinga
News headline image
12 Analysts Assess Apellis Pharmaceuticals: What You Need To Know ↗
During the last three months, 12 analysts shared their evaluations of Apellis Pharmaceuticals (NASDAQ: APLS), revealing diverse outlooks from bullish to bearish. The table below summarizes their recent... 
Via Benzinga
News headline image
Concentrix Posts Downbeat Earnings, Joins Legacy Education, Kingsoft Cloud And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Friday. 
Via Benzinga
Topics Stocks
News headline image
Why Top KingWin Shares Are Trading Higher By 87%; Here Are 20 Stocks Moving Premarket ↗
Shares of Top KingWin Ltd (NASDAQ: WAI) rose sharply in pre-market trading after the company announced it entered into a sales contract with Walker Times International for the sale of 10,000 units of... 
Via Benzinga
Topics Artificial Intelligence
News headline image
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Retail Buzz Surges For Apellis As Goldman Hikes Price Target After Solid Syfovre Sales, FDA Win For Kidney Drug ↗
Goldman Sachs cited Apellis’ 6% quarterly injection growth for Syfovre and potential market upside from Empaveli’s newly approved indications in C3G and IC-MPGN, despite recent revenue headwinds from... 
Via Stocktwits
News headline image
Roblox, Carvana, eBay, C.H. Robinson Worldwide, Huntington Ingalls Industries And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Reports Mixed Q2 2025 Results with EPS Beat and Revenue Miss ↗
Apellis Pharmaceuticals (APLS) reported mixed Q2 2025 results, missing revenue estimates ($178.49M vs. $192.29M) but beating EPS (-$0.33 vs. -$0.49). Shares rose 4.58% pre-market as FDA approval for... 
Via Chartmill
News headline image
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio ↗
FDA approves Apellis' Empaveli for rare kidney diseases, with trial data showing strong efficacy in reducing proteinuria and clearing C3 deposits. 
Via Benzinga
News headline image
Why Retail Investors Are Turning Sharply Bullish On Apellis Pharmaceuticals ↗
The FDA approved Apellis’ drug Empaveli for two rare kidney diseases, following strong results from a Phase 3 trial. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.